.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Baxter
Teva
QuintilesIMS
Queensland Health
Cerilliant
Healthtrust
US Department of Justice
Deloitte
Dow

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075509

« Back to Dashboard

NDA 075509 describes DOXAZOSIN MESYLATE, which is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Apotex, Dava Pharms Inc, Genpharm, Idt Australia Ltd, Ivax Sub Teva Pharms, Mylan, Nesher Pharms, Pliva, Sandoz, Teva, Watson Labs Inc, and Zydus Pharms Usa Inc, and is included in fifteen NDAs. It is available from thirty-three suppliers. Additional details are available on the DOXAZOSIN MESYLATE profile page.

The generic ingredient in DOXAZOSIN MESYLATE is doxazosin mesylate. There are thirteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

Summary for 075509

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Cardiovascular Agents
Genitourinary Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 075509

Mechanism of ActionAdrenergic alpha-Antagonists

Medical Subject Heading (MeSH) Categories for 075509

Suppliers and Packaging for NDA: 075509

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075509 ANDA Mylan Pharmaceuticals Inc. 0378-4021 0378-4021-01 100 TABLET in 1 BOTTLE, PLASTIC (0378-4021-01)
DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075509 ANDA Mylan Pharmaceuticals Inc. 0378-4022 0378-4022-01 100 TABLET in 1 BOTTLE, PLASTIC (0378-4022-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 1MG BASE
Approval Date:Oct 19, 2000TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 2MG BASE
Approval Date:Oct 19, 2000TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 4MG BASE
Approval Date:Oct 19, 2000TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Express Scripts
Chubb
Chinese Patent Office
UBS
Fish and Richardson
Accenture
Citi
Covington
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot